Tag: M.W=500-600

Adding a certain compound to certain chemical reactions, such as: 289042-10-0, N-(5-((Diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound, Recommanded Product: N-(5-((Diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide, blongs to pyrimidines compound. Recommanded Product: N-(5-((Diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide

Sodium bis (trimethylsilyl) amide (1 M in tetrahydrofuran, 23 mi) is added dropwise, AT-74C, to a suspension of the compound of formula (38) (12 g, 22.3 MMOL) in tetrahydrofuran (130 M .). STIRRING is carried out at-74C for 1 hour and then a solution of the compound of formula (40) (6.9 g, 26.8 MMOI) in toluene (28 ML) is added dropwise. Stirring is then carried out AT-74C for 1 hour, then warming to 10C over the course of 1 hour and stirring for a further 1 hour at that temperature. A mixture of acetic acid (2 ml) and water (8.4 ML) is added, at 10C, to the resulting yellow suspension and stirring is carried out at room temperature for 5 minutes. The tetrahydrofuran is then distilled off, and, at 40C, 45 ml of water are added to the reaction mixture and vigorous stirring is carried out for 5 minutes. The aqueous phase is separated off and a solution of sodium hydrogen carbonate (2.27 G) in water (45 ml) is added to the organic phase. Vigorous stirring is again carried out for 5 minutes and then the aqueous phase is removed again. The organic phase is diluted with 250 ML of toluene, washed successively with water and saturated sodium chloride solution and dried (using NA2SO4). The salt mixture is filtered off and the filtrate is concentrated by evaporation. The concentrated residue is then purified by column chromatography on silica gel (hexane: ethyl acetate 8: 1). 2.59 G (61 %) of the desired product (39) can be obtained in the form of colourless crystals. ‘H NMR (300 MHz, CDCI3) : 0.91-1. 08 (m, 1H) ; 1.20 (d, J = 6. 7 HZ, 6H); 1. 24 (S, 3H); 1. 38 (S, 9H); 1.41 (S, 3H); 1.41-1. 56 (m, 1 H) ; 2.21 (dd, J = 15. 2, 7. 9, 1 H) ; 2. 35 (dd, J = 15. 0, 5. 0 HZ, 1H) ; 3. 27-3. 37 (m, 1H) ; 3. 43 (S, 3H); 3.52 (S, 3H); 4.17-4. 24 (m, 1H) ; 4. 47-4. 53 (m, 1H) ; 5.43 (dd, J = 16.4, 5.5 Hz, 1H) ; 6.55 (dd, J = 16.1, 0.8 Hz, 1H) ; 7.24 (dd, J = 8.8, 8.8 HZ, 2H); 7.65 (dd, J = 8.8, 5.6 Hz, 2H). 13C NMR (75 MHz, CDCI3) : 18.7, 20.6, 20.7, 27.0, 29.0, 30.9, 32.0, 35.0, 41.3, 41.4, 64.8, 68.1, 79.6, 97.7, 113.7 (JCF = 21.7 Hz), 120.0, 122.0, 131. 0 (JCF = 8.4 Hz), 133.2 (JCF = 3.2 Hz), 136.3, 156.0, 162.0 (JCF = 249 Hz), 162.2, 168.8, 173.6.

The synthetic route of 289042-10-0 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; CIBA SPECIALTY CHEMICALS HOLDING INC.; WO2004/103977; (2004); A2;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Adding a certain compound to certain chemical reactions, such as: 289042-10-0, N-(5-((Diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound, category: pyrimidines, blongs to pyrimidines compound. category: pyrimidines

40.0 g of compound (DPPO) and 500 ml of THF were added to a 1000 ml four-necked flask.Stir and dissolve, and replace with nitrogen three times.Under nitrogen protection, the internal temperature was lowered to -75.0 C, and 79.0 ml of 1.0 M NaHMDS/THF solution was slowly added dropwise.Control the internal temperature -80.0 C ~ -75.0 C, after the completion of the addition of the reaction, 2.0 h,After the end of the heat preservation reaction, the internal temperature is controlled from -80.0 C to -75.0 C.The compound (D7) THF solution (D7: 23.1 g, THF: 20 ml) was added dropwise, and the reaction was kept for 1.0 h after the dropwise addition;The sample was controlled until the residual of the compound (DPPO) in the reaction solution was ?1.0%, and the reaction was completed. Rise to room temperature,The reaction was quenched by adding 100 ml of a saturated ammonium chloride solution. After quenching, the material was subjected to distillation under reduced pressure at an external temperature of 50.0 C.Vacuum degree ? -0.09MPa, after evaporation to dryness, add 400.0g of toluene to dissolve,It was washed with water, concentrated, and crystallized from 400.0 g of methanol to give compound (R1) 30.0 g.

The synthetic route of 289042-10-0 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; Zhejiang Yongtai Pharmaceutical Co., Ltd.; Wang Xuejin; Xu Xubing; Zhang Chong; Chen Hao; (18 pag.)CN109824606; (2019); A;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

As we all know, there are many different methods for the synthesis of a compound, and people can choose the synthesis method that suits their own laboratory according to the actual situation. 289042-10-0, name is N-(5-((Diphenylphosphoryl)methyl)-4-(4-fluorophenyl)-6-isopropylpyrimidin-2-yl)-N-methylmethanesulfonamide, molecular formula is C28H29FN3O3PS, The compound is widely used in many fields, so it is necessary to find a new synthetic route. The downstream synthesis method of this compound is introduced below. category: pyrimidines

A mixture of DPPO (19.17 g) and THF (227 ml) were warmed briefly to 40 C. until a clear solution had formed then inerted by the sequential application of vacuum and nitrogen (5 cycles). The mixture was immersed in an acetone/CO2 bath cooling the contents to -75 C. Sodium bis(trimethylsilyl)amide (37.4 ml of 1.0 M solution in THF) was added to the reaction mixture over 10 minutes from a pressure equalising dropping funnel maintaining the temperature below -74 C and forming a red solution of the anion. THF (10 ml) was rinsed through the dropping funnel into the mixture and the mixture stirred a further 1 hour at -76 C forming a red suspension. BFA (80 ml of 13.5% w/w toluene solution) was added in portions to the suspension over 20 minutes from a pressure equalising dropping funnel maintaining the temperature below -73 C. Toluene (20 ml) was rinised through the dropping funnel into the mixture and the mixture stirred a further 15 minutes at -76 C. The chilling bath was lowered and the suspension allowed to warm to 10 C over 1.5 hours. Glacial acetic acid (3.21 g) in water (15 g) was added in one portion raising the temperature to 18 C and dissolving all solids and the mixture was stirred a further 5 minutes. The mixture was concentrated by distillation at atmospheric pressure (jacket 110 C) to a temperature of 94 C collecting a total of 274 ml distillates. The concentrated mixture was cooled to 40 C, water (40 ml) was added and the mixture stirred for 5 minutes then allowed to settle for 15 minutes. The lower aqueous phase was discarded. Sodium hydrogen carbonate (2.99 g) in water (40 ml) was added and the mixture stirred for 5 minutes then allowed to settle for 15 minutes. The lower aqueous phase was discarded. Water (30 ml) was added and the mixture stirred for 5 minutes then allowed to settle for 15 minutes. The lower aqueous phase was discarded. The organic phase was transferred to a distillation apparatus with toluene (20 ml) and concentrated by distillation at atmospheric pressure (jacket 125-130 C) to a temperature of 116 C collecting 85 ml distillates. Vacuum was applied (400-500 mbar) and a further 16.5 ml distillates collected to a temperature of 111 C. The vacuum was released and the concentrated mixture allowed to cool to 80 C. Warm MeOH (140 ml, 50 C) was added with rapid stirring and the batch allowed to self-cool to 20 C over 30 minutes during which time a solid was deposited. The suspension was further cooled to 2 C for 30 minutes then the solid was collected by filtration on a sinter and pulled as dry as possible. The solid was washed with cold MeOH (60 ml, 2C.) and again pulled as dry as possible then transferred to a vacuum oven and dried overnight (50 C, 200 mbar); giving BEM (14.01 g, 67.7%). 1H NMR (CDCl3, 270 MHz) 7.65 [m, 2H, ArH], 7.09 [m, 2H, ArH], 6.52 [dd, 1H, ArCH=CH], 5.47 [dd, 1H, ArCH=CH], 3.57, 3.50 [2 x s, 6H, NCH3, SO2CH3], 3.38 [hept., 1H, ArCHMe2], 2.45, 2.30 [2x dd, 2H, CH2CO2tBu], 1.55, 1.13 [dt, dd, 2H, acetonide CH2], 1.50, 1.40 [2x s, 6H, acetonide C(CH3)2], 1.45 [s, 9H, CO2C(CH3)3], 1.27 [dd 6H, ArCH(CH3)2]

With the rapid development of chemical substances, we look forward to future research findings about 289042-10-0.

Reference:
Patent; AstraZeneca AB, AstraZeneca AB; Shionogi & amp Co., Ltd.; US2004/49036; (2004); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Application of 355806-00-7, In the chemical reaction process,reaction time,type of solvent,can easily affect the result of the reaction, thereby determining the yield and properties of the reaction product.An updated downstream synthesis route of 355806-00-7 as follows.

Example 8- (Preparation in Toluene/H20) A 250ML flask equipped with a mechanical stirrer was charged with toluene (25 mL), 5 g t-Butyl-Rosuvastatin, 25 mL H20, 0.75 g of TBAB (tetrabutylammonium bromide) (15% W/W) and 1. 86 g NAOH pellets. The mixture was stirred at ambient temperature for 2 hours. The phases were separated in an apparatus funnel. Traces of toluene in the aqueous phase were distilled off under reduced pressure at 40C to obtain a thick slurry (36.0 g). To this slurry was added 49.5 g CaCl2 1N dropwise. The solution was stirred at ambient temperature for 1.5 hours, filtered and washed with 10 mL of water to get a powdery compound.; Example 10- (preparation in Toluene/H20, 5EQ NAOH)) A 250ML flask equipped with a mechanical stirrer was charged with toluene (25 mL), 5 g t-Butyl-Rosuvastatin, 25 mL H2O, 0.75 g TBAB (tetrabutylammonium bromide) (15% w/w) and 1.86 g NAOH pellets. The mixture was stirred at ambient temperature for 2 hours. The phases were separated in a separation funnel. Traces of toluene in the aqueous phase were distilled off under reduced pressure at 40C to obtain a slurry (24.0 g). Make-up of water was done (26 mL) at the end of the evaporation to obtain a clear solution. To this solution was added 3.3 g CaCl2 IN L0 ML water dropwise. The solution was stirred at ambient temperature for 2 hours, filtered and washed with LOML of water to get a powdery compound.

These compound has a wide range of applications. It is believed that with the continuous development of the source of the synthetic route,355806-00-7, its application will become more common.

Reference:
Patent; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.; WO2005/23778; (2005); A2;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

As we all know, there are many different methods for the synthesis of a compound, and people can choose the synthesis method that suits their own laboratory according to the actual situation. 355806-00-7, name is (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester, molecular formula is C26H36FN3O6S, The compound is widely used in many fields, so it is necessary to find a new synthetic route. The downstream synthesis method of this compound is introduced below. name: (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester

Example 7- (Preparation in ACN/H20) A 250ML flask equipped with a mechanical stirrer was charged with ACN (25 mL), t- Butyl-Rosuvastatin (5 g), H20 (25 mL) and NAOH pellets (1. 86G). The mixture was stirred at ambient temperature for 2 hours. The phases were separated in a separating funnel. The aqueous phase was concentrated under reduced pressure to obtain an oily residue (12.0 g). To this residue was added water (40 ml) and 5.5 g CaCl2. The solution was stirred at ambient temperature for 15 hours (overnight) to form a white precipitate. The organic phase was concentrated under reduced pressure to obtain an oily residue (13.0 g). To this residue were added 40 mL water and 5.5 g CaCl2. The solution was stirred at ambient temperature for 15 hours (over night) to FORM a white precipitate. Both parts were filtered and washed with 10 mL of water to get a powdery compound. (0. 86 g from aqueous phase, 4.01 g from organic phase)

With the rapid development of chemical substances, we look forward to future research findings about 355806-00-7.

Reference:
Patent; TEVA PHARMACEUTICAL INDUSTRIES LTD.; TEVA PHARMACEUTICALS USA, INC.; WO2005/23778; (2005); A2;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Reference of 355806-00-7, The major producers of chemicals have been the Europe, Japan and China. Due to the growing call for a cleaner, greener environment, people will have to find innovative ways to maintain their relevance. Here is a compound 355806-00-7, name is (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-isopropyl-2-[(methanesulfonyl) methylamino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid tert-butyl ester. This compound has unique chemical properties. The synthetic route is as follows.

Example 7; General procedure for preparing isolated ammonium salts of rosuvastatin; 5 g of terf-butyl ester of rosuvastatin 1.75 ml of 8 M NaOH 25 ml of demineralized water 10 ml of tetrahydrofuran EPO The reactants and the solvents are stirred from 50 to 55C for 1 hour. The solution formed is then allowed to cool to room temperature and washed with 50 ml methylcyclohexane yielding 33 ml of aqueous solution of sodium salt of rosuvastatin.To 33 ml of sodium rosuvastatinate solution prepared in the above described experiment is added 1.3 ml 85% phosphoric acid, previously dissolved in 5 ml of water. Reaction mixture is extracted with 40 ml of /so-butyl acetate. Organic layer is separated off and dried with 5 g of anhydrous magnesium sulphate. Drying agent is filtered off and washed with 10 ml /so-butyl acetate obtaining 52 ml of filtrate containing rosuvastatinic acid, which is divided into smaller portions for preparing various ammonium salts.To 5 ml of the obtained solution 1.5 equivalents of appropriate amine and 5 ml tert-butyl methyl ether are added. Rosuvastatin substituted ammonium salt is filtered off and dried on filter. The following solid salts are prepared:cyclohexylammonium salt of rosuvastatin: 0.45 g, 99.71% area by HPLC;1H-NMR: (CD3OD): 1.10 – 1.45 (12H,m), 1.31 (6H,d, J=7Hz), 1.48 – 1.56 (1H,m), 1.62 – 1.72 (1 H,m), 1.80 – 1.87 (2H,m), 1.97 – 2.03 (2H,m), 2.25 (1H,dd, J1=MHz, J2=7.6Hz), 2.34 (1H,dd, J1=MHz1 J2=4.9Hz), 2.98 – 3.09 (1 H,m), 3.51 (1H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 – 3.97 (1H,m), 4.33 – 4.40 (1H,m), 5.56 (1 H,dd, J1=^Hz, J2=6Hz), 6.62 (1H,dd, J1=^Hz, J2=1.2Hz), 7.14 – 7.22 (2H,m), 7.69 – 7.75 (1H,m);dicyclohexylammonim salt of rosuvastatin: 0.35 g, 99.82% area;1H-NMR: (CD3OD): 1.12 – 1.76 (20H,m), 1.29 (d, J=7Hz), 1.48 – 1.56 (1H,m), 1.62 – 1.72 (1H,m), 1.83 – 1.92 (4H,m), 2.01 – 2.09(4H,m), 2.25 (1H,dd, J1=HHz, J2=7,6Hz), 2.34 (1H,dd, J1=MHz, J2=4.9Hz), 3.07 – 3.17 (2H,m), 3.51 (1H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 – 3.97 (1H,m), 4.33 – 4.40 (1H,m), 5.56 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1H,dd, J,=16Hz, J2=1.2Hz), 7.14 – 7.22 (2H,m), 7.69 – 7,75 (2H,m);pyrrolidinium salt of rosuvastatin: 0.28 g, 99.71% area,1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.48 – 1.56 (1H,m), 1.62 – 1.72 (1H,m), 1.96 – 2.01 (4H,m), 2.25 (1H,dd, J1=MHz, J2=7,6Hz), 2.34 (1H,dd, J1=MHz, J2=4,9Hz), 3.20 – 3.25 (4H,m), 3,51 (1H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 – 3.97 (1 H,m), 4.33 – 4.40 EPO (1 H,m), 5.56 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1 H,dd, J1=IeHz, J2=1 ,2Hz), 7.14 – 7.22 (2H,m), 7.69 – 7.75 (2H,m);piperidinium salt of rosuvastatin: 0.28 g, 99.77% area;1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.48 – 1.56 (1H,m), 1.62 – 1.81 (7H,m), 2.25 (1 H,dd, J1=MHz, J2=7.6Hz), 2,34 (1 H,dd, J1=MHz, J2=4,9Hz), 3.09 – 3.13 (4H,m), 3.51 (1 H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 – 3.97 (1H,m), 4.33 – 4.40 (1 H,m), 5.56 (1 H,dd, J1=IeHz, J2=6Hz), 6.62 (1H,dd, J1=^Hz, J2=1.2Hz), 7.14 – 7,22 (1H,m), 7.69 – 7.75 (2H,m);morpholinium salt of rosuvastatin: 0.30 g, 99.51% area;1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.49 – 1.57 (1 H,m), 1.62 – 1.72 (1H,m), 2.25 (1 H,dd, J1=MHz, J2=7.6Hz), 2.34 (1 H,dd, J1=HHz, J2=4.9Hz), 3.12 – 3.16 (4H,m), 3.51 (1 H,h, J=7Hz), 3.52 (3H,s), 3.53 (3H,s), 3.81 – 3.,85 (4H,m), 3.92 – 4.00 (1H,m), 4.33 – 4.40 (1H,m), 5.57 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1H,dd, J1=IeHz, J2=1.2Hz), 7.14 – 7.22 (2H,m), 7.69 – 7.75 (1H,m);1-adamantylammonium salt of rosuvastatin: 0.66 g, 99.75% area;1H-NMR: (CD3OD): 1.29 (6H,d, J=7Hz), 1.48 – 1.56 (1H,m), 1.62 – 1.85 (16H,m), 2.15 (3H,s (broad)), 2.25 (1 H,dd, J1=HHz, J2=7,6Hz), 2.34 (1H,dd, J1=UHz, J2=4.9Hz), 3.51 (1 H,h, J=7Hz), 3.52 (3H,s), 3.54 (3H,s), 3.92 – 3.97 (1H,m), 4.33 – 4.40 (1 H,m), 5.56 (1H,dd, J1=IeHz, J2=6Hz), 6.62 (1 H,dd, J1=^Hz, J2=1.2Hz), 7.14 – 7.22 (2H,m), 7.69 – 7.75 (1 H,m).; Example 8; Preparation of N-cyclohexylammonium salt of rosuvastatin; 1O g tert-butyl ester of rosuvastatin3.5 ml 8 M NaOH50 ml demineralized water20 ml tetrahydrofuran EPO The reactants and the solvents are stirred from 50 to 55C for 1 hour. The solution formed is then allowed to cool to room temperature and washed with 100 ml methylcyclohexane yielding 66 ml of aqueous solution of sodium rosuvastatinate.To 33 ml of the obtained solution is added 1.3 ml 85% phosphoric acid in 5 ml demineralized water. Rosuvastatinic acid is extracted with 40 ml /so-propyl acetate. 4.7 g of anhydrous magnesium sulphate and 0.5 g charcoal is added to organic phase and suspension is stirred for 45 min. Magnesium sulphate and charcoal are filtered off yielding 41 ml of filtrate.16 ml of the filtrate is separated and treated by addition of 0.5 ml of cyclohexylamine in 8 ml of /so-propyl acetate during stirring and rosuvastatin cyclohexylammonium salt precipitate instantaneously as white solid. It is separated by filtration, precipitate is washed on the filter with 10 ml of /so-propyl acetate and dried on the filter yielding 1.34 g of the de…

According to the analysis of related databases, 355806-00-7, the application of this compound in the production field has become more and more popular.

Reference:
Patent; LEK PHARMACEUTICALS D.D.; WO2006/136407; (2006); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Application of 274693-26-4, As we all know, there are many different methods for the synthesis of a compound, and people can choose the synthesis method that suits their own laboratory according to the actual situation. 274693-26-4, name is 2-(((3aR,4S,6R,6aS)-6-(7-(((1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol, molecular formula is C26H32F2N6O4S, The compound is widely used in many fields, so it is necessary to find a new synthetic route. The downstream synthesis method of this compound is introduced below.

TGRL-6 (16 mol) in toluene was added dropwise a mixture of concentrated hydrochloric acid (17.88 kg) and methanol (28.6 L). The addition was complete, the reaction was stirred at 5 C 3h. Phase, remove the toluene phase. Configure sodium bicarbonate(18. lkg), water (26.6kg) and ethyl acetate (24kg) was added dropwise to a mixture of methanol phase and sodium bicarbonate. Dropping is completed, phase, retaining the upper organic phase. Add organic phase activated carbon bleaching. Filter and concentrate the organic phase to a solid. Got ticagrelor 5.7kg, The total yield of 57%, purity96.85%, impurity N 1.2%

According to the analysis of related databases, 274693-26-4, the application of this compound in the production field has become more and more popular.

Reference:
Patent; Huizhou Xinlitai Pharmaceutical Co., Ltd.; Shenzhen Xinlitai Pharmaceutical Co., Ltd.; Xu Wenjie; Wang Shangwen; Liu Junguang; Li Song; Hua Huaijie; (11 pag.)CN105153167; (2017); B;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Application of 274693-26-4, As we all know, there are many different methods for the synthesis of a compound, and people can choose the synthesis method that suits their own laboratory according to the actual situation. 274693-26-4, name is 2-(((3aR,4S,6R,6aS)-6-(7-(((1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol, molecular formula is C26H32F2N6O4S, The compound is widely used in many fields, so it is necessary to find a new synthetic route. The downstream synthesis method of this compound is introduced below.

TGRL-6 (16 mol) in toluene was added dropwise a mixture of concentrated hydrochloric acid (17.88 kg) and methanol (28.6 L). The addition was complete, the reaction was stirred at 5 C 3h. Phase, remove the toluene phase. Configure sodium bicarbonate(18. lkg), water (26.6kg) and ethyl acetate (24kg) was added dropwise to a mixture of methanol phase and sodium bicarbonate. Dropping is completed, phase, retaining the upper organic phase. Add organic phase activated carbon bleaching. Filter and concentrate the organic phase to a solid. Got ticagrelor 5.7kg, The total yield of 57%, purity96.85%, impurity N 1.2%

According to the analysis of related databases, 274693-26-4, the application of this compound in the production field has become more and more popular.

Reference:
Patent; Huizhou Xinlitai Pharmaceutical Co., Ltd.; Shenzhen Xinlitai Pharmaceutical Co., Ltd.; Xu Wenjie; Wang Shangwen; Liu Junguang; Li Song; Hua Huaijie; (11 pag.)CN105153167; (2017); B;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

The major producers of chemicals have been the Europe, Japan and China. Due to the growing call for a cleaner, greener environment, people will have to find innovative ways to maintain their relevance. Here is a compound 274693-26-4, name is 2-(((3aR,4S,6R,6aS)-6-(7-(((1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol. This compound has unique chemical properties. The synthetic route is as follows. COA of Formula: C26H32F2N6O4S

Hydrochloric acid (3N, 24 mL) was added to a solution of 2-(((3aR,4S,6R,6aS)-6-(7-(((1R,2S)-2-(3,4-difluorophenyl)cyclopropyl)amino)-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d](1,3)dioxol-4-yl)oxy)ethanol (6 g, Formula XI as obtained from Example 10) in methanol (30 mL). The reaction mixture was heated to 35C to 40C. The reaction mixture was stirred for 16 hours at 35C to 40C. Methanol was distilled off completely under vacuum at 30C to 35C to obtain a residue. The residue was extracted with dichloromethane (36 mL). The organic layer was washed with aqueous hydrochloric acid (IN, 30 mL) followed by washing with aqueous sodium bicarbonate solution (3 g in 30 mL) and deionized water (30 mL). The organic layer was distilled off to dryness to obtain a crude material. The crude material was purified with acetonitrile (30 mL) to afford the title compound. Yield: 4.16 g

With the rapid development of chemical substances, we look forward to future research findings about 274693-26-4.

Reference:
Patent; SUN PHARMACEUTICAL INDUSTRIES LIMITED; GOTTUMUKKALA, Nagaraju; SAINI, Anil; KHANNA, Mahavir, Singh; PRASAD, Mohan; (56 pag.)WO2016/38520; (2016); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Electric Literature of 274693-26-4, With the rapid development and complex challenges of chemical substances, the synthesis of new drugs is usually one of the most effective ways to increase yield.274693-26-4, name is 2-(((3aR,4S,6R,6aS)-6-(7-(((1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol, molecular formula is C26H32F2N6O4S, molecular weight is 562.63, as common compound, the synthetic route is as follows.

Charge (2.6 gm) of compound 28 in (8-10 Vol.) of Methanol at Room temperature. Charge dilute HC1 (1.4 gm) at RT. Stir the reaction mass for 24 hours at RT. Upon completion of the reaction checked by TLC, the reaction mass was brought to slightly acidic pH of 6-6.5 by using dilute aq. NaOH. Upon removal of methanol under vacuum and extracting organic mass with ethyl acetate and further washing this organic layer with brine and concentration of ethyl acetate under vacuum gave crude Ticagrelor 1. Further purification of Ticagrelor 1. was carried out by crystallization from a mixture of ethyl acetate and heptane to provide white to off-white solid. The purity of Ticagrelor 1 was 99.6% (HPLC). Some of the characteristic and selective peaks (delta value) in -NMR (CDG13) for 1 are 7.5 (s, 1H), 6.83 – 7.2 (m, 3H), 5.67 (m, 1 H), 5.04 (m, 1H), 4.82 (m, 1H), 4.13 (m, 1H), 3.6 – 3.9 (m, 4H), 3.2 (t, 2H), 1.57 (m, 2H), 0.79 (t, 3H).

Statistics shows that 274693-26-4 is playing an increasingly important role. we look forward to future research findings about 2-(((3aR,4S,6R,6aS)-6-(7-(((1R,2S)-2-(3,4-Difluorophenyl)cyclopropyl)amino)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol.

Reference:
Patent; ANLON CHEMICAL RESEARCH ORGANIZATION; RASADIA, Punitkumar Rameshbhai; RAMANI.Vaibhav Narendrakumar; PANDEY, Bipin; BHADANI, Vijay Nagjibhai; VACHHANI, Dipakkumar Dhanjibhai; SHAH, Anamik Kantilal; WO2015/162630; (2015); A1;,
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia